ALZN vs ANL

Alzamend Neuro, Inc. vs Adlai Nortye Ltd. — Valuation Comparison 2026

ALZN

Biotechnology
Alzamend Neuro, Inc.
Quality
4.1
out of 10
Value Trap
12
SAFE
Price
$1.15
Last close
Models
7/13
Active
VS

ANL

Biotechnology
Adlai Nortye Ltd.
Quality
1.5
out of 10
Value Trap
12
SAFE
Price
$11.30
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ALZN Fair ValueALZN Upside ANL Fair ValueANL Upside
Bayesian DCF Intrinsic $0.70 -39.3% $2.99 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.05 -95.4% $0.61 -95.5%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $7.86 -49.3%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ALZN vs ANL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ALZN vs ANL — Which Stock Is More Undervalued?

ALZN scores higher with a 4.1/10 quality rating vs ANL's 1.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alzamend Neuro, Inc. (ALZN) and Adlai Nortye Ltd. (ANL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ALZN currently trades at $1.15 with a QOC of 4.1/10, while ANL trades at $11.30 with a QOC of 1.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).